124 related articles for article (PubMed ID: 35918816)
1. Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA.
Wu P; Zhang H; Sun M; Mao S; He Q; Shi Y; Deng Y; Dong Z; Xu Q; Zhao C; Zhang W; Sun B
Adv Mater; 2022 Sep; 34(38):e2203019. PubMed ID: 35918816
[TBL] [Abstract][Full Text] [Related]
2. Synergetic regulation of cancer cells and exhausted T cells to fight cold tumors with a fluorinated EGCG-based nanocomplex.
Zhang J; Wang M; He D; Zhang L; Liu T; Wang K
J Nanobiotechnology; 2023 Nov; 21(1):420. PubMed ID: 37957632
[TBL] [Abstract][Full Text] [Related]
3. Microfluidics-enabled fluorinated assembly of EGCG-ligands-siTOX nanoparticles for synergetic tumor cells and exhausted t cells regulation in cancer immunotherapy.
Han X; Zhang G; Wu X; Xu S; Liu J; Wang K; Liu T; Wu P
J Nanobiotechnology; 2024 Mar; 22(1):90. PubMed ID: 38439048
[TBL] [Abstract][Full Text] [Related]
4. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
Zang X; Song J; Yi X; Piyu J
J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
[TBL] [Abstract][Full Text] [Related]
8. Nanoassembly of doxorubicin-conjugated polyphosphoester and siRNA simultaneously elicited macrophage- and T cell- mediated anticancer immune response for cancer therapy.
Li D; Cao Z; Chen C; Li H; He S; Hou X; Liang M; Yang X; Wang J
Biomaterials; 2023 Nov; 302():122339. PubMed ID: 37778054
[TBL] [Abstract][Full Text] [Related]
9. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Activation Protein-α Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.
Sun M; Yao S; Fan L; Fang Z; Miao W; Hu Z; Wang Z
Small; 2022 Mar; 18(9):e2106296. PubMed ID: 34914185
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
12. Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug.
Yang Z; Luo X; Lin Y; Huang J; Lin H; Gao J
ACS Chem Biol; 2022 Apr; 17(4):762-767. PubMed ID: 35285234
[TBL] [Abstract][Full Text] [Related]
13. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
14. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer.
Li S; Wang S; Zhang A; Luo L; Song J; Wei G; Fang Z
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38391053
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
17. Prodrug-Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death.
Bai S; Yang LL; Wang Y; Zhang T; Fu L; Yang S; Wan S; Wang S; Jia D; Li B; Xue P; Kang Y; Sun ZJ; Xu Z
Small; 2020 May; 16(19):e2000214. PubMed ID: 32309900
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
19. Codelivered Chemotherapeutic Doxorubicin
Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
[TBL] [Abstract][Full Text] [Related]
20. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery.
Kyu Shim M; Yang S; Sun IC; Kim K
Adv Drug Deliv Rev; 2022 Apr; 183():114177. PubMed ID: 35245568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
